Biopharma Boardroom speaks with Hubert Martens, CEO of Salvia BioElectronics, about the development of the MySalvia System, an investigational implantable ...
SOTERIA Precision Medicine Foundation (SOTERIA), a California-based 501(c)(3) nonprofit, announces Cancer Hunt™, a nationwide precision oncology prog...
Rakovina Therapeutics Inc. (TSX-V: RKV) (FSE: 7JO0) (OTCMKTS: RKVTF), a biopharmaceutical company advancing innovative cancer therapies through AI-powered ...
As demand for Exatecan-based antibody-drug conjugates (ADCs) grows, securing reliable manufacturing capacity and diversified supply chains has become a pri...
– Etentamig is a second-generation BCMA-directed bispecific antibody T-cell engager with a clinical profile and dosing schedule that can pote...
OTXL-101, a promising therapy in development for a severe, rare pediatric metabolic condition, becomes the first pipeline program to be in-licensed by Or...
SEKISUI Diagnostics, a global medical diagnostics manufacturer, has announced the launch of a 510(k) cleared rapid test to detect COVID-19 and Flu A&...
CellsBin®, a biotechnology company pioneering Rare-Cell Biology™, announced that it has received a Direct-to-Phase II Small Business Innov...
Powered by whole-genome sequencing and MAESTRO* technology, the next-generation Oncodetect test takes a distinct approach to MRD,...
Made Scientific to integrate multiple UniFuge® single-use centrifugation systems across its Princeton, NJ, and East Norriton, PA, facilities to suppo...
Golden Age Health is co-founded and chaired by Michel Vounatsos, former Biogen CEO and Merck President Kos Biotechnology Partners ("Kos"), a global ...
Late-breaking results to be presented in an oral presentation at ESMO 2026 PANKU-Lung01 is the first Phase 3 trial to evaluate a dual-targeting EGFRxHER...
BioAgilytix, a global bioanalytical Contract Research Organization (CRO), announces the expansion of its Australian laboratories through the op...
82% objective response rate, median progression-free survival (PFS) not yet reached, and 9-month PFS-rate of 88% in patients with 2L/3L pancreatic cancer t...
© 2026 Biopharma Boardroom. All Rights Reserved.
